Is Zero A Must?: The Impact Of Residual Symptoms In Major Depressive Disorder
While remission is the goal in treatment of patients with major depressive disorder (MDD), persistent symptoms are common, even among remitters, and can negatively affect patient functioning and outcomes. In this webinar, Allen Doederlein, Robert Nelson, MD, and Madhukar Trivedi, MD, review the prevalence and burden of MDD, discuss the burden of inadequate treatment of MDD and the prevalence and impact of residual symptoms, and review strategies for addressing residual symptoms in patients with MDD.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.